A novel prognostic risk-scoring system based on m5C methylation regulator-mediated patterns for glioma patients
N5-methylcytosine (m5C) methylation modification plays a crucial role in the epigenetic mechanisms underlying tumorigenesis, aggressiveness, and malignancy in diffuse glioma. Our study aimed to develop a novel prognostic risk-scoring system to assess the impact of m5C modification in glioma patients...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-06-01
|
| Series: | Molecular Therapy: Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2950329924000328 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850162606886617088 |
|---|---|
| author | Yutong Wen Xiaotong Chen Runtong Li Haiting Xie Shuai Zhi Kaitao Wang Shang Yi Wen Liang Haiyan Hu Shitao Rao Xiaoya Gao |
| author_facet | Yutong Wen Xiaotong Chen Runtong Li Haiting Xie Shuai Zhi Kaitao Wang Shang Yi Wen Liang Haiyan Hu Shitao Rao Xiaoya Gao |
| author_sort | Yutong Wen |
| collection | DOAJ |
| description | N5-methylcytosine (m5C) methylation modification plays a crucial role in the epigenetic mechanisms underlying tumorigenesis, aggressiveness, and malignancy in diffuse glioma. Our study aimed to develop a novel prognostic risk-scoring system to assess the impact of m5C modification in glioma patients. Initially, we identified two distinct m5C clusters based on the expression level of m5C regulators in The Cancer Genome Atlas glioblastoma (TCGA-GBM) dataset. Differentially expressed genes (DEGs) between the two m5C cluster groups were determined. Utilizing these m5C regulation-related DEGs, we classified glioma patients into three gene cluster groups: A, B, and C. Subsequently, an m5C scoring system was developed through a univariate Cox regression model, quantifying the m5C modification patterns utilizing six DEGs associated with disease prognosis. The resulting scoring system allowed us to categorize patients into high- or low-risk groups based on their m5C scores. In test (TCGA-GBM) and validation (Chinese Glioma Genome Atlas [CGGA]-1018 and CGGA-301) datasets, glioma patients with a higher m5C score consistently exhibited shorter survival durations, fewer isocitrate dehydrogenase (IDH) mutations, less 1p/19q codeletion and higher World Health Organization (WHO) grades. Additionally, distinct immune cell infiltration characteristics were observed among different m5C cluster groups and risk groups. Our study developed a novel prognostic scoring system based on m5C modification patterns for glioma patients, complementing existing molecular classifications and providing valuable insights into prognosis for glioma patients. |
| format | Article |
| id | doaj-art-769249cb3b68468eaadbd8255fe61dc9 |
| institution | OA Journals |
| issn | 2950-3299 |
| language | English |
| publishDate | 2024-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Molecular Therapy: Oncology |
| spelling | doaj-art-769249cb3b68468eaadbd8255fe61dc92025-08-20T02:22:32ZengElsevierMolecular Therapy: Oncology2950-32992024-06-0132220079010.1016/j.omton.2024.200790A novel prognostic risk-scoring system based on m5C methylation regulator-mediated patterns for glioma patientsYutong Wen0Xiaotong Chen1Runtong Li2Haiting Xie3Shuai Zhi4Kaitao Wang5Shang Yi6Wen Liang7Haiyan Hu8Shitao Rao9Xiaoya Gao10Department of Neurology, Zhujiang Hospital of Southern Medical University, 253 Gongye Avenue, Guangzhou, Guangdong 510282, P.R. ChinaDepartment of Bioinformatics, Fujian Key Laboratory of Medical Bioinformatics, School of Medical Technology and Engineering, Fujian Medical University, Fuzhou 350122, China; Key Laboratory of Ministry of Education for Gastrointestinal Cancer, School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350122, ChinaDepartment of Neurology, Zhujiang Hospital of Southern Medical University, 253 Gongye Avenue, Guangzhou, Guangdong 510282, P.R. ChinaDepartment of Neurology, Zhujiang Hospital of Southern Medical University, 253 Gongye Avenue, Guangzhou, Guangdong 510282, P.R. ChinaDepartment of Bioinformatics, Fujian Key Laboratory of Medical Bioinformatics, School of Medical Technology and Engineering, Fujian Medical University, Fuzhou 350122, China; Key Laboratory of Ministry of Education for Gastrointestinal Cancer, School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350122, ChinaDepartment of Neurology, Zhujiang Hospital of Southern Medical University, 253 Gongye Avenue, Guangzhou, Guangdong 510282, P.R. ChinaDepartment of Neurology, Zhujiang Hospital of Southern Medical University, 253 Gongye Avenue, Guangzhou, Guangdong 510282, P.R. ChinaDepartment of Radiology, Zhujiang Hospital of Southern Medical University, 253 Gongye Avenue, Guangzhou, Guangdong 510282, P.R. ChinaDepartment of Oncology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, P.R. China; Corresponding author: Haiyan Hu, MD, PhD, Department of Oncology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, P.R. China.Department of Bioinformatics, Fujian Key Laboratory of Medical Bioinformatics, School of Medical Technology and Engineering, Fujian Medical University, Fuzhou 350122, China; Key Laboratory of Ministry of Education for Gastrointestinal Cancer, School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350122, China; Corresponding author: Shitao Rao, MD, PhD, Department of Bioinformatics, Fujian Key Laboratory of Medical Bioinformatics, School of Medical Technology and Engineering, Fujian Medical University, Fuzhou 350122, China.Department of Neurology, Zhujiang Hospital of Southern Medical University, 253 Gongye Avenue, Guangzhou, Guangdong 510282, P.R. China; Department of Pediatric Neurology, Zhujiang Hospital of Southern Medical University, 253 Gongye Avenue, Guangzhou, Guangdong 510282, P.R. China; Corresponding author: Xiaoya Gao, PhD, Department of Pediatric Neurology, Zhujiang Hospital of Southern Medical University, 253 Gongye Avenue, Guangzhou, Guangdong 510282, P.R. China.N5-methylcytosine (m5C) methylation modification plays a crucial role in the epigenetic mechanisms underlying tumorigenesis, aggressiveness, and malignancy in diffuse glioma. Our study aimed to develop a novel prognostic risk-scoring system to assess the impact of m5C modification in glioma patients. Initially, we identified two distinct m5C clusters based on the expression level of m5C regulators in The Cancer Genome Atlas glioblastoma (TCGA-GBM) dataset. Differentially expressed genes (DEGs) between the two m5C cluster groups were determined. Utilizing these m5C regulation-related DEGs, we classified glioma patients into three gene cluster groups: A, B, and C. Subsequently, an m5C scoring system was developed through a univariate Cox regression model, quantifying the m5C modification patterns utilizing six DEGs associated with disease prognosis. The resulting scoring system allowed us to categorize patients into high- or low-risk groups based on their m5C scores. In test (TCGA-GBM) and validation (Chinese Glioma Genome Atlas [CGGA]-1018 and CGGA-301) datasets, glioma patients with a higher m5C score consistently exhibited shorter survival durations, fewer isocitrate dehydrogenase (IDH) mutations, less 1p/19q codeletion and higher World Health Organization (WHO) grades. Additionally, distinct immune cell infiltration characteristics were observed among different m5C cluster groups and risk groups. Our study developed a novel prognostic scoring system based on m5C modification patterns for glioma patients, complementing existing molecular classifications and providing valuable insights into prognosis for glioma patients.http://www.sciencedirect.com/science/article/pii/S2950329924000328gliomam5C modificationm5C score risk systemdisease prognosticsTME immune components |
| spellingShingle | Yutong Wen Xiaotong Chen Runtong Li Haiting Xie Shuai Zhi Kaitao Wang Shang Yi Wen Liang Haiyan Hu Shitao Rao Xiaoya Gao A novel prognostic risk-scoring system based on m5C methylation regulator-mediated patterns for glioma patients Molecular Therapy: Oncology glioma m5C modification m5C score risk system disease prognostics TME immune components |
| title | A novel prognostic risk-scoring system based on m5C methylation regulator-mediated patterns for glioma patients |
| title_full | A novel prognostic risk-scoring system based on m5C methylation regulator-mediated patterns for glioma patients |
| title_fullStr | A novel prognostic risk-scoring system based on m5C methylation regulator-mediated patterns for glioma patients |
| title_full_unstemmed | A novel prognostic risk-scoring system based on m5C methylation regulator-mediated patterns for glioma patients |
| title_short | A novel prognostic risk-scoring system based on m5C methylation regulator-mediated patterns for glioma patients |
| title_sort | novel prognostic risk scoring system based on m5c methylation regulator mediated patterns for glioma patients |
| topic | glioma m5C modification m5C score risk system disease prognostics TME immune components |
| url | http://www.sciencedirect.com/science/article/pii/S2950329924000328 |
| work_keys_str_mv | AT yutongwen anovelprognosticriskscoringsystembasedonm5cmethylationregulatormediatedpatternsforgliomapatients AT xiaotongchen anovelprognosticriskscoringsystembasedonm5cmethylationregulatormediatedpatternsforgliomapatients AT runtongli anovelprognosticriskscoringsystembasedonm5cmethylationregulatormediatedpatternsforgliomapatients AT haitingxie anovelprognosticriskscoringsystembasedonm5cmethylationregulatormediatedpatternsforgliomapatients AT shuaizhi anovelprognosticriskscoringsystembasedonm5cmethylationregulatormediatedpatternsforgliomapatients AT kaitaowang anovelprognosticriskscoringsystembasedonm5cmethylationregulatormediatedpatternsforgliomapatients AT shangyi anovelprognosticriskscoringsystembasedonm5cmethylationregulatormediatedpatternsforgliomapatients AT wenliang anovelprognosticriskscoringsystembasedonm5cmethylationregulatormediatedpatternsforgliomapatients AT haiyanhu anovelprognosticriskscoringsystembasedonm5cmethylationregulatormediatedpatternsforgliomapatients AT shitaorao anovelprognosticriskscoringsystembasedonm5cmethylationregulatormediatedpatternsforgliomapatients AT xiaoyagao anovelprognosticriskscoringsystembasedonm5cmethylationregulatormediatedpatternsforgliomapatients AT yutongwen novelprognosticriskscoringsystembasedonm5cmethylationregulatormediatedpatternsforgliomapatients AT xiaotongchen novelprognosticriskscoringsystembasedonm5cmethylationregulatormediatedpatternsforgliomapatients AT runtongli novelprognosticriskscoringsystembasedonm5cmethylationregulatormediatedpatternsforgliomapatients AT haitingxie novelprognosticriskscoringsystembasedonm5cmethylationregulatormediatedpatternsforgliomapatients AT shuaizhi novelprognosticriskscoringsystembasedonm5cmethylationregulatormediatedpatternsforgliomapatients AT kaitaowang novelprognosticriskscoringsystembasedonm5cmethylationregulatormediatedpatternsforgliomapatients AT shangyi novelprognosticriskscoringsystembasedonm5cmethylationregulatormediatedpatternsforgliomapatients AT wenliang novelprognosticriskscoringsystembasedonm5cmethylationregulatormediatedpatternsforgliomapatients AT haiyanhu novelprognosticriskscoringsystembasedonm5cmethylationregulatormediatedpatternsforgliomapatients AT shitaorao novelprognosticriskscoringsystembasedonm5cmethylationregulatormediatedpatternsforgliomapatients AT xiaoyagao novelprognosticriskscoringsystembasedonm5cmethylationregulatormediatedpatternsforgliomapatients |